Hanna G Kaspar1, Christopher P Crum. 1. From the Department of Laboratory Medicine, Geisinger Health System, Wilkes-Barre, Pennsylvania (Dr Kaspar);
Abstract
CONTEXT: Immunohistochemistry has assumed an increasing role in the identification and characterization of gynecologic disorders including lesions with deceptively bland morphology, uncommon and underdiagnosed neoplasms, and neoplasms with specific genetic alterations associated with overexpression or loss of expression of specific proteins. The diagnostic accuracy has been significantly improved owing to the discovery and increasing experience with the tumor-associated biomarkers, and the increasing demand for precise tumor classification to assess suitability for the expanding therapeutic modalities including clinical trials. OBJECTIVE: To differentiate lesions of the gynecologic tract through the use of effective immunohistochemical panels. DATA SOURCES: Literature review and authors' personal practice experience. CONCLUSIONS: The application of diagnostic and prognostic immunohistochemical panels has enabled pathologists to better guide therapeutic decisions and to better predict the clinical outcome. It is now well established that the use of ancillary testing, including immunohistochemistry, has a significant power in the identification, differentiation, and classification of reactive, premalignant, and malignant gynecologic disorders. This article discusses the utilities and pitfalls of the commonly used immunohistochemical markers in the context of overlapping morphologic features encountered in the uterus, ovaries, and fallopian tubes.
CONTEXT: Immunohistochemistry has assumed an increasing role in the identification and characterization of gynecologic disorders including lesions with deceptively bland morphology, uncommon and underdiagnosed neoplasms, and neoplasms with specific genetic alterations associated with overexpression or loss of expression of specific proteins. The diagnostic accuracy has been significantly improved owing to the discovery and increasing experience with the tumor-associated biomarkers, and the increasing demand for precise tumor classification to assess suitability for the expanding therapeutic modalities including clinical trials. OBJECTIVE: To differentiate lesions of the gynecologic tract through the use of effective immunohistochemical panels. DATA SOURCES: Literature review and authors' personal practice experience. CONCLUSIONS: The application of diagnostic and prognostic immunohistochemical panels has enabled pathologists to better guide therapeutic decisions and to better predict the clinical outcome. It is now well established that the use of ancillary testing, including immunohistochemistry, has a significant power in the identification, differentiation, and classification of reactive, premalignant, and malignant gynecologic disorders. This article discusses the utilities and pitfalls of the commonly used immunohistochemical markers in the context of overlapping morphologic features encountered in the uterus, ovaries, and fallopian tubes.
Authors: Rebecca C Arend; Michael D Toboni; Allison M Montgomery; Robert A Burger; Alexander B Olawaiye; Bradley J Monk; Thomas J Herzog Journal: Oncologist Date: 2018-08-23
Authors: Anna Schuh; Helene Dreau; Samantha J L Knight; Kate Ridout; Tuba Mizani; Dimitris Vavoulis; Richard Colling; Pavlos Antoniou; Erika M Kvikstad; Melissa M Pentony; Angela Hamblin; Andrew Protheroe; Marina Parton; Ketan A Shah; Zsolt Orosz; Nick Athanasou; Bass Hassan; Adrienne M Flanagan; Ahmed Ahmed; Stuart Winter; Adrian Harris; Ian Tomlinson; Niko Popitsch; David Church; Jenny C Taylor Journal: Cold Spring Harb Mol Case Stud Date: 2018-04-02
Authors: Andrzej Pyra; Aneta Adamiak-Godlewska; Dorota Lewkowicz; Beata Bałon; Marek Cybulski; Anna Semczuk-Sikora; Andrzej Semczuk Journal: Oncol Lett Date: 2022-08-31 Impact factor: 3.111
Authors: Felix Leung; Marcus Q Bernardini; Kun Liang; Ihor Batruch; Marjan Rouzbahman; Eleftherios P Diamandis; Vathany Kulasingam Journal: F1000Res Date: 2018-02-14
Authors: Dan Weng; Tao Han; Jin Dong; Ming Zhang; Yang Mi; Yiping He; Xiaojuan Li; Xiaoming Zhu Journal: Medicine (Baltimore) Date: 2022-02-04 Impact factor: 1.889